Pictilisib (GDC-0941)

Catalog No.S1065 Synonyms: RG7321

Molecular Weight(MW): 513.64

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

Cited by 114 Publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Nature, 2014, 508(7494):118-22

PubMed: 24670642 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Cancer Res, 2019, 79(6):1138-1150

PubMed: 30679179 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Int J Cancer, 2019, 145(3):817-829

PubMed: 30671946 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):41

PubMed: 30691487 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):236

PubMed: 31164152 ( click the link to review the publication )

Cells, 2019, 8(2)

PubMed: 30795621 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Blood, 2018, 10.1182/blood-2018-08-872465

PubMed: 30322870 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Cell Rep, 2018, 22(4):860-868

PubMed: 29420173 ( click the link to review the publication )
Oncogene, 2018, 37(10):1369-1385

PubMed: 29311642 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):1881-1896

PubMed: 30132519 ( click the link to review the publication )

Proteomics, 2018, 18(23):e1800244

PubMed: 30267477 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0193849

PubMed: 29799846 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):611-618

PubMed: 28494242 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(18):5561-5572

PubMed: 28606920 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1892-1904

PubMed: 28108509 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0415

PubMed: 28119489 ( click the link to review the publication )

Oncogenesis, 2017, 6(11):398

PubMed: 29184057 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52877-52888

PubMed: 28881779 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1345-1356

PubMed: 27117832 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )
Nat Commun, 2015, 6:7212

PubMed: 25998442 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1591

PubMed: 25590801 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: 25292196 ( click the link to review the publication )

J Biol Chem, 2015, 290(40):24367-80

PubMed: 26294766 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: 25327687 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4597-4611

PubMed: 25183785 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

Oncogene, 2014, 33(23):3043-53

PubMed: 23893244 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )
Neoplasia, 2014, 16(2):147-57

PubMed: 24709422 ( click the link to review the publication )

J Immunol, 2014, 193(6):3036-44

PubMed: 25092892 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84746

PubMed: 24404189 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Anticancer Drugs, 2014, 25(2):183-8

PubMed: 24100276 ( click the link to review the publication )

Harvard University, 2014,

PubMed: ( click the link to review the publication )

Blood, 2013, 121(12):2274-84

PubMed: 23341541 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Leukemia, 2013, 27(11):2118-28

PubMed: 23535559 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Oncogene, 2013, 33(9):1190-7

PubMed: 23435426 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1099-108

PubMed: 23345407 ( click the link to review the publication )

Cancer Sci, 2013, 104(8):1027-32

PubMed: 23710822 ( click the link to review the publication )

J Biol Chem, 2013, 288(21):14698-708

PubMed: 23585567 ( click the link to review the publication )

Cancer Med, 2013, 2(1):76-85

PubMed: 24133630 ( click the link to review the publication )

FEBS Lett, 2013, 587(1):5-16

PubMed: 23178716 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66306

PubMed: 23824914 ( click the link to review the publication )

Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )
Clin Cancer Res, 2012, 18(9):2502-14

PubMed: 22351686 ( click the link to review the publication )

Clin Cancer Res, 2012, 19(3):657-67

PubMed: 23251002 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(31):E2127-33

PubMed: 22773810 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e400

PubMed: 23059819 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 5):1259-73

PubMed: 22399812 ( click the link to review the publication )

Cancer Sci, 2012, 103(9):1665-71

PubMed: 22703543 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(12):2210-6

PubMed: 22974639 ( click the link to review the publication )

J Leukoc Biol, 2012, 92(1):219-31

PubMed: 22544939 ( click the link to review the publication )

Mol Cell Biol, 2012, 32(22):4674-83

PubMed: 22988297 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(24):7595-604

PubMed: 22038996 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(8):2260-9

PubMed: 21220474 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(37):E699-708

PubMed: 21876152 ( click the link to review the publication )

Cancer Res, 2011, 71(7):2750-60

PubMed: 21317224 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(2):495-503

PubMed: 21048785 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)
3 nM	3 nM	33 nM	75 nM	0.58 μM(Ki app)

In vitro

GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. ^[1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. ^[2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. ^[3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Sf9	NHq5emJMcW6jc3WgRZN{[Xl?		NYn1[WhvOSCq	NH7INoxFVVOR	NWrxN\|cxUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDk[Yx1[SCneIDy[ZN{\WRiaX6gV4Y6KGOnbHzzJINw\XiycnXzd4lv\yCyOEXhcJBp[SC5aYToJGlEPTBib3[gNE4xODNizszN	NYnZTHZQOTh5NUS2OVQ>
Sf9	M2jnemtqdmG\|ZTDBd5NigQ>?		NYXrZ3NFOSCq	NHT3WZhFVVOR	MoOxTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCkZYThJGgyODR5LWKgcZV1[W62IHX4dJJme3OnZDDpckBU\jliY3XscJMh[2:neIDy[ZN{cW6pIIC4OYFteGijIIfpeIghUUN3MDDv[kAxNjByMzFOwG0>	MW[xPFc2PDZ3NB?=
Sf9	NITJdJdMcW6jc3WgRZN{[Xl?		NVyzTXFROSCq	MVfEUXNQ	MnziTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCkZYThJGU2PDVvSzDteZRidnRiZYjwdoV{e2WmIHnuJHNnQSClZXzsd{Bkd2W6cILld5NqdmdicEi1ZYxxcGFid3n0bEBKSzVyIH;mJFAvODB\|IN88US=>	M4HTSVE5PzV2NkW0
Sf9	MWTLbY5ie2ViQYPzZZk>		NHTYZlMyKGh?	MVPEUXNQ	MVnJcohq[mm2aX;uJI9nKGi3bXHuJJJm[2:vYnnuZY51KFCLM1ugdFEyOGKndHGg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyClb3X4dJJme3OrbnegdFg2[WyyaHGge4l1cCCLQ{WwJI9nKDBwMEOzJO69VQ>?	NYrMO3cxOTh5NUS2OVQ>
Sf9	M1;0cWtqdmG\|ZTDBd5NigQ>?		NETtZo8yKGh?	MnLzSG1UVw>?	MnrmTY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCjbIDoZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IHPv[ZhxemW\|c3nu[{BxQDWjbIDoZS=>	MkDZNVg4PTR4NUS=
MDA-MB-361	NFjtSppHfW6ldHnvckBCe3OjeR?=		MWGyJIg>	NFHjUIpFVVOR	MXzJcohq[mm2aX;uJI9nKEGtdDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKE2GQT3NRk0{PjFiY3XscJMhf2m2aDDQTWs{S0FiRUW0OU1MKG23dHH0bY9vKHerdHigTWM2OCCxZjCwMlAzQCEQvF2=	NX7EPZBYOTh5NUS2OVQ>
PC3	NYDlT4ZZTnWwY4Tpc44hSXO\|YYm=		M4DRdVIhcA>?	MXvEUXNQ	M3j1VWlvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25iaX6gVHRGVi2wdXzsJIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yM{eg{txO	MVyxPFc2PDZ3NB?=
U87MG	NHq5Vo5HfW6ldHnvckBCe3OjeR?=		MUmyJIg>	NHT1d3BFVVOR	NGLuWJZKdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHnuJHBVTU5vboXscEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFnDOVAhd2ZiMD6wOFYh\|ryP	MX2xPFc2PDZ3NB?=
MDA-MB-361	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MlvFPVYhcA>?	NVvuS4p2TE2VTx?=	MYTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2GQT3NRk0{PjFiY3XscJMhf2m2aDDQTWs{S0FiRUW0OU1MKG23dHH0bY9vKHerdHigTWM2OCCxZjCwMlczKM7:TR?=	NEPLbJMyQDd3NE[1OC=>
A2780	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUXTW2pmQTZiaB?=	NETxWJBFVVOR	NXTXUms6SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIGDJT\|NESSCjbnSgVHRGViCvdYTheIlwdiC5aYToJGlEPTBib3[gNE4yPCEQvF2=	MXixPFc2PDZ3NB?=
PC3	NGfwPVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHjiO3A6PiCq	NFnMV\|dFVVOR	MXTJR\|UxRTBwMkig{txO	MU[xPFc2PDZ3NB?=
U87MG	NEn4fplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmLnPVYhcA>?	NWnjcW1qTE2VTx?=	MYjJR\|UxRTBwOUWg{txO	M3rGb\|E5PzV2NkW0
Sf9	NH7Xc2FMcW6jc3WgRZN{[Xl?		MkjoN\|AhdWmw	M4X1ZmROW09?	MnHSTY5pcWKrdHnvckBw\iCqdX3hckBRUTONZ3HtcYEh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHHtc5VvfCCxZjDBWHAh[2:wc4Xt[YQhf2m2aDDJR\|UxKG:oIECuNFQzKM7:TR?=	MX2yNlU1QDN2Mh?=
RAW 264.7	NGi2SmdMcW6jc3WgRZN{[Xl?		NELGNJo6OCCvaX6=	MY\EUXNQ	NGjqVYhKdmirYnn0bY9vKG:oIHj1cYFvKFCLM1vnZY1u[SCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCDS2SgdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjJ7ODFOwG0>	MVWyNlU1QDN2Mh?=
Sf9	NH\3cmZMcW6jc3WgRZN{[Xl?		NXfaSY1ZOSCq		NFjUU5FKdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM[mW2YTDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU1[5JINmdGy\|IIfpeIghUUN3MDDv[kAxNjBzNzFOwG0>	NXHy[XE4OjN3NEC2OFU>
Sf9	NInWdpZMcW6jc3WgRZN{[Xl?		MVWxJIg>		MW\Jcohq[mm2aX;uJI9nKEeVVD3meZNm\CCqdX3hckBz\WOxbXLpcoFvfCCSSUPL[IVtfGFiZYjwdoV{e2Wm	NGjXVpEzOzV2ME[0OS=>
Sf9	NVXiO44zU2mwYYPlJGF{e2G7		MkLjNUBp		M4rXcWlvcGmkaYTpc44hd2ZiR2PUMYZ2e2WmIHj1cYFvKHKnY3;tZolv[W62IGDJN2to[W2vYTDlfJBz\XO\|ZXS=	MYiyN\|U1ODZ2NR?=
Sf9	NEHWfolMcW6jc3WgRZN{[Xl?		NV;lRpVuOSCq		NGT6T5BKdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM[WyyaHGg[ZhxemW\|c3Xk	NH7WcJMzOzV2ME[0OS=>
SKOV3	MV7LbY5ie2ViQYPzZZk>	M33xZVEh\|ryP	NEfzRnQyKGh?	M1f1OGROW09?	M{n6WmlvcGmkaYTpc44hd2ZiUFmzT4FteGijIHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25?	M1TZbVI{OzZyM{S4
MCF7	NIPsc4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYGxJO69VQ>?	MXe5OkBp	MkHxSG1UVw>?	NH\wUFFIUTVyPUCuNFcxOiEQvF2=	M1q3fVI{OzZyM{S4
SKOV3	Ml36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYPJPJhEOSEQvF2=	M2[zVFk3KGh?	M4HqfWROW09?	NWHTN\|I2T0l3ME2wMlE1PzZizszN	NIfiS4gzOzN4MEO0PC=>
PC3	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1XGXFczKGh?	NEHTXXRFVVOR	NFvJU5RKSzVyPUCuNlgh\|ryP	NWDtPHZkOjF7OEG3NVQ>
MCF7.1	NX;1UFNuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MoPjO\|IhcA>?	NH3oWWlFVVOR	NYHpSpc3SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4NjFiY3XscJMh\XiycnXzd4lv\yCKRWKyJIdmdmVid3n0bEBKSzVyIH;mJFAvOjhizszN	NF;NXHkzOTl6MUexOC=>
MCF7-neo/Her2	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M37hbVczKGh?	M3nwcGROW09?	NVm0e4lFUUN3ME2wMlI6KM7:TR?=	NF;BfmIzOzZ4MkmwNy=>
MCF7-neo/Her2	NHiwdFRMcW6jc3WgRZN{[Xl?				NELzO3FKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZiQVvUJJBpd3OyaH;yfYxifGmxbjDheEBUPDd\|IIfpeIghUUN3MDDv[kAxNjByNzFOwG0>	MmL5NlM3PjJ7MEO=
PC3	MmLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MkP0O\|IhcA>?	NEPXd4pFVVOR	Mk\4SWM2OD1yLkO0JO69VQ>?	NGfjRYMzOTl6NU[zPS=>
MCF7.1	NIXWNo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEKzeGQ4OiCq	NFTRcnBFVVOR	M3foOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{4yKGOnbHzzJIV5eHKnc4PpcochWEl\|S3HsdIhiKG23dHHueEB4cXSqIFXDOVAhd2ZiMD6zPUDPxE1?	M4S2blIyQTh3NkO5
PC3	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUO3NkBp	NYHKTJp[TE2VTx?=	NEHZWZJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczDk[YZq[2mnboSgbY4hWFSHTjD3bZRpKEmFNUCgc4YhOC5\|OTFOwG0>	MVOyNFA2ODZ4OR?=
MCF7.1	NGPNXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Ml\UO\|IhcA>?	M4HvOmROW09?	NFzJR2xCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlcvOSClZXzsd{BmgHC{ZYPzbY5oKFCLM1vhcJBp[SCvdYThcpQhf2m2aDDJR\|UxKG:oIECuN\|Qh\|ryP	NEe5RpEzODB3ME[2PS=>
MCF7.1	NIjFc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MYS3NkBp		M4PCUWVEPTB;MD63NkDPxE1?	NEHmWmgzODN2Nk[1Oi=>
NCI-H1975	NUDNbpdvS3m2b4TvfIlkKEG\|c3H5		Mn;wO\|IhcA>?		NVfYNFZMUUN3ME2wMlI4KM7:TR?=	M2Phc\|I{ODV7NUS1
H460	NVTpR2JHS3m2b4TvfIlkKEG\|c3H5		MnzJO\|IhcA>?		MXTJR\|UxRTBwOEeg{txO	MXSyN\|A2QTV2NR?=
HT-29	NVvUR2t[S3m2b4TvfIlkKEG\|c3H5		NUXEfoFRPzJiaB?=		NUi1Xog5UUN3ME2wMlY3KM7:TR?=	MUGyN\|A2QTV2NR?=
HepG2	MVTDfZRwfG:6aXOgRZN{[Xl?		NF20[YU4OiCq		MWrJR\|UxRTFizszN	NWjvUFBOOjNyNUm1OFU>
SGC7901	MXTDfZRwfG:6aXOgRZN{[Xl?		NVjpXndtPzJiaB?=		MkXlTWM2OD1zLkig{txO	NVmwPINwOjNyNUm1OFU>
NCI-H226	NEH5OGhEgXSxdH;4bYMhSXO\|YYm=		NXziSZRtPzJiaB?=		M4D6[2lEPTB;Mj65JO69VQ>?	MmXTNlMxPTl3NEW=
A549	MYjDfZRwfG:6aXOgRZN{[Xl?		NF\I[lI4OiCq		Mn7CTWM2OD14Lkmg{txO	MVSyN\|A2QTV2NR?=
U87MG	NE\pUItEgXSxdH;4bYMhSXO\|YYm=		MYG3NkBp		NW\5NHl1UUN3ME23Mlc4KM7:TR?=	NGPWbIkzOzB3OUW0OS=>
HBC4	MonCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3Be4xLdG:pR1m1NF0uPi5yMzDN	MkW5NlI{OzZ{NE[=
BSY1	MmPDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX20flVzdG:pR1m1NF0uPi57MDDN	NIPRZ2MzOjN\|NkK0Oi=>
HBC5	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPsc4dIUTVyPT22MlYxKE1?	NXzuZpl6OjJ\|M{[yOFY>
MCF7	M4\Rb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkS5cI9oT0l3ME2tO{4{OyCP	MXOyNlM{PjJ2Nh?=
MDA-MB-231	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDsc4dIUTVyPT21MlQ3KE1?	MkP5NlI{OzZ{NE[=
U251	M3vHZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3;wfIxw\0eLNUC9MVUvPTBiTR?=	MV2yNlM{PjJ2Nh?=
SF268	M1Hvb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmn0cI9oT0l3ME2tOU4{QSCP	M2jBb\|IzOzN4MkS2
SF295	NXjvOGdZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV3VSHZ[dG:pR1m1NF0uPi5\|NzDN	M{SyelIzOzN4MkS2
SF539	M{Pj[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;TTFhtd2eJSUWwQU03NjVyIF2=	Mn;VNlI{OzZ{NE[=
SNB75	NHv6cmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULsc4dIUTVyPT23MlExKE1?	M12wU\|IzOzN4MkS2
SNB78	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVHsc4dIUTVyPT22MlUzKE1?	MYmyNlM{PjJ2Nh?=
HCC2998	MoTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofscI9oT0l3ME2tOk4zQSCP	MVmyNlM{PjJ2Nh?=
KM12	NEDSSW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIG0VJZtd2eJSUWwQU02Njd4IF2=	M2rmOFIzOzN4MkS2
HT-29	NI\WUnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXqSnRNdG:pR1m1NF0uPi5\|MDDN	MlzsNlI{OzZ{NE[=
HCT15	NHH5N\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXhdmtKdG:pR1m1NF0uPi5zMjDN	Mm\nNlI{OzZ{NE[=
HCT116	NEHkdI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYr3V2hEdG:pR1m1NF0uPS56NzDN	M2\1cFIzOzN4MkS2
NCI-H23	NGCyfmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17qRoxw\0eLNUC9MVUvPzNiTR?=	NEfLUYszOjN\|NkK0Oi=>
NCI-H226	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDNcI9oT0l3ME2tOk4zOSCP	MWiyNlM{PjJ2Nh?=
NCI-H522	NFHnfJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF:zR2dtd2eJSUWwQU03NjV6IF2=	MmTwNlI{OzZ{NE[=
NCI-H483	MkXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnCcI9oT0l3ME2tOk42PiCP	NHThUIwzOjN\|NkK0Oi=>
A549	M2mxS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVT4bHIxdG:pR1m1NF0uPi5zNTDN	NIrUSVczOjN\|NkK0Oi=>
DMS273	MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIfScpZtd2eJSUWwQU03NjR\|IF2=	NV64eJpuOjJ\|M{[yOFY>
DMS114	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFXtcVVtd2eJSUWwQU02Njl{IF2=	NH7QZY0zOjN\|NkK0Oi=>
LOXIMVI	NEHK[pVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDNcI9oT0l3ME2tOk4zQSCP	MV6yNlM{PjJ2Nh?=
OVCAR3	M2j5Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zpPYxw\0eLNUC9MVYvPzFiTR?=	MoDWNlI{OzZ{NE[=
OVCAR4	NEPCNFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXnsc4dIUTVyPT21Mlc3KE1?	NWr5Onc3OjJ\|M{[yOFY>
OVCAR5	NXW2OlFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoWzcI9oT0l3ME2tOk4zPiCP	MVeyNlM{PjJ2Nh?=
OVCAR8	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvsUFdidG:pR1m1NF0uPS55MzDN	MmDINlI{OzZ{NE[=
SKOV3	NU\VWWt[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3q1[oxw\0eLNUC9MVYvPTJiTR?=	NHHWcGYzOjN\|NkK0Oi=>
RXF631L	NHiwZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{\IZYxw\0eLNUC9MVYvQDhiTR?=	M3yyZlIzOzN4MkS2
ACHN	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHyW3Jtd2eJSUWwQU03NjB5IF2=	MVuyNlM{PjJ2Nh?=
St-4	Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGf0T3Ftd2eJSUWwQU02NjV4IF2=	M2LC[VIzOzN4MkS2
MKN1	M3v2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfsc4dIUTVyPT23MlA5KE1?	MlzTNlI{OzZ{NE[=
MKN7	MnP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXL2eIFsdG:pR1m1NF0uPi53MDDN	MmDPNlI{OzZ{NE[=
MKN28	M33JOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DmXoxw\0eLNUC9MVUvPTJiTR?=	M2TtSFIzOzN4MkS2
MKN45	NFHZWIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;sSlhtd2eJSUWwQU03NjV3IF2=	MUKyNlM{PjJ2Nh?=
MKN74	MoXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nlZ4xw\0eLNUC9MVYvODJiTR?=	MYCyNlM{PjJ2Nh?=
DU145	MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH:5S\|Vtd2eJSUWwQU02Njh3IF2=	MmjuNlI{OzZ{NE[=
PC3	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTsc4dIUTVyPT22MlY3KE1?	MYSyNlM{PjJ2Nh?=
ES5	NIHYZ\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{n2bmlEPTB;NUCuNlEhdk1?	M{TCe3NCVkeHUh?=
HH	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\S[mlEPTB;MUGxMlA5KG6P	MX7TRW5ITVJ?
MHH-PREB-1	NILZRZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXy0WmhsUUN3ME2xNVQvOyCwTR?=	MX\TRW5ITVJ?
NCI-H1770	M37rcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTF{Mz64OkBvVQ>?	M{TnWnNCVkeHUh?=
HuO9	Mkn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFjPNXRKSzVyPUKwOk4xOiCwTR?=	Mn3sV2FPT0WU
HAL-01	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYH1dIROUUN3ME2yNFYvPzNibl2=	NX3yXnhkW0GQR1XS
NOS-1	M3vZVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlzkTWM2OD1{MUGuPFIhdk1?	MlrCV2FPT0WU
HGC-27	M3Ha[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\sO\|ZKSzVyPUKxNk42PyCwTR?=	M2\RTnNCVkeHUh?=
NB69	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfXTWM2OD1{NEWuNlchdk1?	M4HLbnNCVkeHUh?=
RS4-11	NYjrdW9KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mni3TWM2OD1{NkGuO\|Yhdk1?	M2XUWXNCVkeHUh?=
DOK	NXX4c3JiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLqTWM2OD1\|MEGuO{BvVQ>?	MWrTRW5ITVJ?
LB2241-RCC	NUntTmlET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTNyMz64OEBvVQ>?	MlPhV2FPT0WU
NCI-H1623	NWDzfnN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmm2TWM2OD1\|MESuNFghdk1?	NFjlNm1USU6JRWK=
YH-13	M3vnZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUWwRZpGUUN3ME2zNFQvOzJibl2=	MXTTRW5ITVJ?
BPH-1	NVPMZmdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUDJR\|UxRTNzNDDuUS=>	MUfTRW5ITVJ?
AN3-CA	NVTrPHBkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTN2MD6zO{BvVQ>?	NVf2bWN2W0GQR1XS
ES7	MnvCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEnxWZZKSzVyPUO0NU46QSCwTR?=	NWjnXIR3W0GQR1XS
MDA-MB-175-VII	M2TnS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWrHcI1{UUN3ME2zOVIvQTJibl2=	Mo\iV2FPT0WU
GAMG	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTN5MD64OUBvVQ>?	MkXJV2FPT0WU
CHL-1	NH7tRoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXOSmNUUUN3ME2zO\|gvPjVibl2=	M2jjb3NCVkeHUh?=
NB7	M1HId2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTN6OT64N{BvVQ>?	MmS5V2FPT0WU
MFE-280	NV30RVhHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzO[o1KSzVyPUSxPE4zKG6P	MoHpV2FPT0WU
HL-60	MmTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3Xrd2lEPTB;NEK1Mlc2KG6P	MlH1V2FPT0WU
GCIY	NUK3cWlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mnf2TWM2OD12M{OuPEBvVQ>?	MmLZV2FPT0WU
MDA-MB-361	M{X4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmj1TWM2OD12M{muNVMhdk1?	NU\5e2dmW0GQR1XS
LXF-289	M37NVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXH2b\|lrUUN3ME20OFgvOjdibl2=	MWHTRW5ITVJ?
NBsusSR	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoD3TWM2OD12OEiuPFUhdk1?	NFiyUZVUSU6JRWK=
KU-19-19	M3\RXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTtTWM2OD13MU[uNFchdk1?	NYe1UIdPW0GQR1XS
A204	NV3tO45TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nac2lEPTB;NUKyMlM{KG6P	NWexeXNnW0GQR1XS
LB1047-RCC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTV{Mj65N{BvVQ>?	MlHsV2FPT0WU
COLO-684	NUL2VmFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXXSlBKSzVyPUWyN{4yOSCwTR?=	MUHTRW5ITVJ?
PA-1	NEjNd2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFy0[XFKSzVyPUWzNk41OSCwTR?=	M1XUV3NCVkeHUh?=
MG-63	MoPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zEXGlEPTB;NUSxMlEyKG6P	MmXsV2FPT0WU
BHT-101	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;rVWlEPTB;NUS0Mlk1KG6P	NHS1PFFUSU6JRWK=
NKM-1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{f1fmlEPTB;NUmzMlA6KG6P	MliyV2FPT0WU
T47D	NHTPZolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XNV2lEPTB;NUm3MlU3KG6P	MX3TRW5ITVJ?
MOLT-4	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX;mc5d4UUN3ME22NlMvPjJibl2=	M{\ESHNCVkeHUh?=
IGROV-1	NFG0S4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknXTWM2OD14M{SuN\|Ehdk1?	MmC0V2FPT0WU
ES4	M2TyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH:0d2tKSzVyPU[zPU42PCCwTR?=	MUHTRW5ITVJ?
HuO-3N1	MlK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NISwcVFKSzVyPU[0Nk4{QCCwTR?=	M3jIZ3NCVkeHUh?=
NEC8	NUH3eFZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLHTWM2OD14NUOuOVchdk1?	NWrQXHFbW0GQR1XS
HO-1-N-1	NWHqTY1YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTZ3OT6xO{BvVQ>?	M3;YUXNCVkeHUh?=
EPCL-272H	NVT5SYZUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\ZR4RKSzVyPU[4O{4zOSCwTR?=	M1XJRnNCVkeHUh?=
D-263MG	M{\xOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHKzZ\|hKSzVyPUexPE4yKG6P	MkK2V2FPT0WU
MV-4-11	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1n1bWlEPTB;N{K0MlMyKG6P	MnjXV2FPT0WU
SK-NEP-1	Mmm2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2K3c2lEPTB;N{K1Mlk1KG6P	NXW5cGVOW0GQR1XS
SW872	NWXKTVdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX21b\|dUUUN3ME23NlcvQDlibl2=	NGrOVWpUSU6JRWK=
P30-OHK	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTRTWM2OD15M{CuO\|Ehdk1?	MWnTRW5ITVJ?
OMC-1	NIPCSJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HCeGlEPTB;N{WxMlA6KG6P	Ml;hV2FPT0WU
LoVo	M3HLfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTd5Nz65JI5O	M4S4WnNCVkeHUh?=
LNCaP-Clone-FGC	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrHbIFNUUN3ME23PVYvOzRibl2=	M4LGOnNCVkeHUh?=
L-363	MoXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrnTWM2OD15OUiuOFIhdk1?	M4TBUnNCVkeHUh?=
ES8	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUjWTXNoUUN3ME24NVAvPTJibl2=	NVjWb3l1W0GQR1XS
697	NVzURlZOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm[0TWM2OD16M{GuOVUhdk1?	NFrP[GRUSU6JRWK=
HSC-3	MkL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLLTWM2OD16M{muOVQhdk1?	MXfTRW5ITVJ?
H4	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\hcnFKSzVyPUi1NE45PSCwTR?=	MYXTRW5ITVJ?
QIMR-WIL	M1LiNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVXJR\|UxRTh4NT6yJI5O	NETpUXNUSU6JRWK=
OAW-42	NHL4RlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTh5Mj6xPUBvVQ>?	NG\vN\|hUSU6JRWK=
MCF7	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljHTWM2OD16OUiuOVkhdk1?	MnfxV2FPT0WU
SCC-25	NIi3WVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXv5NpVoUUN3ME25NVQvOTlibl2=	Ml74V2FPT0WU
NCI-H1563	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLCTWM2OD17MUWuPVkhdk1?	MlnmV2FPT0WU
OVCAR-5	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlz5TWM2OD17NECuNVchdk1?	M{G5RnNCVkeHUh?=
HDLM-2	MoLzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmTGTWM2OD17NEmuNkBvVQ>?	M{ixRnNCVkeHUh?=
NB5	M1nKbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvETFhzUUN3ME25OVYvPiCwTR?=	MVPTRW5ITVJ?
NCI-H292	M3m1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVPBb3l1UUN3ME25O\|QvOzJibl2=	MV3TRW5ITVJ?
A101D	NInvWJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF35S3lKSzVyPUm5NE4yQSCwTR?=	MVPTRW5ITVJ?
NCI-H1648	MoLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLKTWM2OD17OUiuOVEhdk1?	NUTBb3RiW0GQR1XS
EKVX	NWLWW4JuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF\NPXVKSzVyPUGuNFEzQSEQvF2=	NXTBSItlW0GQR1XS
SW1710	NXXSeYZNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLQWW5QUUN3ME2xMlA1OjN\|IN88US=>	M{HGV3NCVkeHUh?=
WM-115	NFnBU3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDWS4pKSzVyPUGuNFY3PTZizszN	MmTuV2FPT0WU
CAL-54	M4jjOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTFwMEewPFEh\|ryP	M3r4bXNCVkeHUh?=
TGBC24TKB	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2WyR2lEPTB;MT6wPFA1PSEQvF2=	Ml3vV2FPT0WU
NCI-H520	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHiTWM2OD1zLkC4PVY4KM7:TR?=	NXjMb4htW0GQR1XS
D-423MG	MnrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHHTWM2OD1zLkC5PVYzKM7:TR?=	NHvQTXVUSU6JRWK=
BFTC-905	NGXIPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1j4XWlEPTB;MT6xN\|Q1QSEQvF2=	M1v4RXNCVkeHUh?=
HT	MnzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3PTWM2OD1zLkGzOFc5KM7:TR?=	MkP4V2FPT0WU
CTB-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVztVVZkUUN3ME2xMlE1Ojl\|IN88US=>	M17Te3NCVkeHUh?=
Hs-578-T	M1nvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;ZUGZ[UUN3ME2xMlE6PTZ3IN88US=>	MYLTRW5ITVJ?
HuH-7	MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;nTWM2OD1zLkKwPVQ6KM7:TR?=	NInrS4tUSU6JRWK=
LB996-RCC	Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnLUTWM2OD1zLkKyNVc4KM7:TR?=	MWTTRW5ITVJ?
KYSE-270	Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLpWoNuUUN3ME2xMlI6PzN2IN88US=>	MYPTRW5ITVJ?
A4-Fuk	M2nk[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXz5Z3ozUUN3ME2xMlI6QTl\|IN88US=>	MmfZV2FPT0WU
A498	M3viV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXy1NFF7UUN3ME2xMlMxPDd2IN88US=>	NVf0NVVLW0GQR1XS
SK-MEL-1	M1u4TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTFwM{C2O\|kh\|ryP	MXnTRW5ITVJ?
AU565	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{LBSmlEPTB;MT6zNVg3OyEQvF2=	MmDUV2FPT0WU
Saos-2	M4DpT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHvlblZKSzVyPUGuN\|MzODVizszN	NFjEVYFUSU6JRWK=
A549	MlPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUDJR\|UxRTFwM{m5O{DPxE1?	M4\vWXNCVkeHUh?=
BFTC-909	M37VOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjzPFFKSzVyPUGuOFM{ODVizszN	MoDuV2FPT0WU
MDA-MB-415	M4fWRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTFwNEi2PVIh\|ryP	NEPlSJVUSU6JRWK=
639-V	NVW2XnRwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV:zOZhFUUN3ME2xMlUxOjR3IN88US=>	NF7nVnpUSU6JRWK=
A704	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoLBTWM2OD1zLkWwO\|g2KM7:TR?=	M1PuR3NCVkeHUh?=
PANC-03-27	M{LidGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTFwNUG0NFgh\|ryP	NYHhfZZiW0GQR1XS
SK-MEL-28	M{m3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTSbVlKSzVyPUGuOVYxQDVizszN	MnjpV2FPT0WU
Ramos-2G6-4C10	Mmm0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGq3SVdKSzVyPUGuOlA4PDZizszN	Moe2V2FPT0WU
HuP-T4	NYe4Uo96T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3HFWGlEPTB;MT62NFc4QCEQvF2=	MlfpV2FPT0WU
VA-ES-BJ	NGjsWWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTWTWM2OD1zLk[xNlch\|ryP	NGnDTXpUSU6JRWK=
EFM-19	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTFwNkG4NUDPxE1?	MnvXV2FPT0WU
G-401	MnXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrHVIVpUUN3ME2xMlYzOTZ2IN88US=>	MULTRW5ITVJ?
D-566MG	NGH1T2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4n3fGlEPTB;MT62NlU{KM7:TR?=	NWizNpVxW0GQR1XS
JVM-3	NEX3XYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTFwNkS4O\|Uh\|ryP	MYXTRW5ITVJ?
TK10	NYPMXpB5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYLSO5FOUUN3ME2xMlY4ODh\|IN88US=>	NH;tNmxUSU6JRWK=
BT-20	MlS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4jjXmlEPTB;MT62PFkxOiEQvF2=	M4DZOnNCVkeHUh?=
EGI-1	MmjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PG[WlEPTB;MT64OFcxOSEQvF2=	MUjTRW5ITVJ?
EW-16	MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHaeVJHUUN3ME2xMlg2OTh{IN88US=>	NF3KUWFUSU6JRWK=
NCI-H2228	NV3NWmJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4KxcWlEPTB;MT64OVIxOyEQvF2=	M1TPRXNCVkeHUh?=
BB49-HNC	NF\yb2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3TXeGlEPTB;MT64PFY6OiEQvF2=	MknaV2FPT0WU
G-402	MmS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTFwOEm3PVch\|ryP	MmPIV2FPT0WU
NCI-H526	MmiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTFwOUGzPUDPxE1?	MYTTRW5ITVJ?
ME-180	MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTFwOUO0O\|ch\|ryP	NF7ofWVUSU6JRWK=
PFSK-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4TMd2lEPTB;MT65OFQ2QCEQvF2=	MX7TRW5ITVJ?
TYK-nu	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUf4S5VUUUN3ME2xMlk2QDJ\|IN88US=>	NU\WTHN{W0GQR1XS
HOS	MnHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3ewVmlEPTB;MT65O\|k1QCEQvF2=	M3XJOXNCVkeHUh?=
T98G	NEPETFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPMV5hKSzVyPUGuPVkxODZizszN	NFvoNYxUSU6JRWK=
SK-MES-1	MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{\ITGlEPTB;Mj6wNVM{OiEQvF2=	M17oS3NCVkeHUh?=
SNB75	M4jxfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rtcmlEPTB;Mj6wNVU1OSEQvF2=	MWPTRW5ITVJ?
LAMA-84	MnvWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGLvcHpKSzVyPUKuNFI3QDlizszN	NVHn[5hIW0GQR1XS
CAL-39	M2DUcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDE[GpKSzVyPUKuNFMzQCEQvF2=	Mlv3V2FPT0WU
LOXIMVI	NFziWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlT0TWM2OD1{LkC0NFg1KM7:TR?=	M4HUOHNCVkeHUh?=
NH-12	NUjZR4t3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTJwMEW0NlQh\|ryP	MmjvV2FPT0WU
NCI-H1048	NV\1UmZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfKbpN{UUN3ME2yMlExPTJizszN	NYTkdZBDW0GQR1XS
KS-1	NFHtTINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoS3TWM2OD1{LkGxNFAyKM7:TR?=	MXjTRW5ITVJ?
NCI-N87	NHi2cXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmS2TWM2OD1{LkGzN\|g1KM7:TR?=	M3W4XXNCVkeHUh?=
CHP-212	MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVj0THZbUUN3ME2yMlE5PDR{IN88US=>	M{XzNHNCVkeHUh?=
HCC1419	MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLhTWM2OD1{LkKxNVE2KM7:TR?=	M325R3NCVkeHUh?=
ES1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7DN3BKSzVyPUKuNlE{OjZizszN	M{PTXnNCVkeHUh?=
NCI-H2030	M{\jZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NI[wOGNKSzVyPUKuNlQyOjNizszN	NWS1[495W0GQR1XS
EW-22	NF3KdXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXWXmxKSzVyPUKuNlUxPjdizszN	NYHU[ZRNW0GQR1XS
A431	MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvwTWM2OD1{LkK3N\|U1KM7:TR?=	MoHQV2FPT0WU
SF126	M{PwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17HSWlEPTB;Mj6zNFYzPSEQvF2=	NFfSTlRUSU6JRWK=
SF295	MnSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDYTWM2OD1{LkOxOVI1KM7:TR?=	NGqzVJJUSU6JRWK=
D-502MG	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTJwM{K0OlEh\|ryP	MWnTRW5ITVJ?
HCC2157	MlW4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\DcGdKSzVyPUKuN\|I6OjdizszN	M3vsUnNCVkeHUh?=
D-283MED	Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MW\JR\|UxRTJwM{W5NlYh\|ryP	Mk\JV2FPT0WU
SNU-423	M1zvd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2j4dGlEPTB;Mj60NFE4OSEQvF2=	NXf1cmRNW0GQR1XS
SK-LU-1	NHr0RmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHadJE1UUN3ME2yMlQ1PTh4IN88US=>	NWfzRoVHW0GQR1XS
22RV1	NU\6So5tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TmcmlEPTB;Mj60OVYyPyEQvF2=	MnfXV2FPT0WU
SW1088	NELURWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGH4bGZKSzVyPUKuOFkzOTNizszN	MmnCV2FPT0WU
HT-3	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml25TWM2OD1{LkS5NlU6KM7:TR?=	MUjTRW5ITVJ?
NCI-H1666	M{XTdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTJwNUGxNFQh\|ryP	M{frVHNCVkeHUh?=
EM-2	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjhUpBKSzVyPUKuOVEyPjlizszN	NX\E[XBiW0GQR1XS
SNU-449	M37IPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTJwNUewNVQh\|ryP	NYXZOWRkW0GQR1XS
786-0	NWXqeW5VT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTGbJBbUUN3ME2yMlU6OjN6IN88US=>	NWrSRlhRW0GQR1XS
SKG-IIIa	M{fzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmqzTWM2OD1{Lk[1PVM6KM7:TR?=	MkfmV2FPT0WU
MEL-HO	NH:1OXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTJwNke2N\|Qh\|ryP	NEfnSI1USU6JRWK=
LCLC-97TM1	MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPmdXVKSzVyPUKuOlkzPjdizszN	Mme3V2FPT0WU
MKN7	NH3UZ4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIrD[3BKSzVyPUKuO\|A4PTRizszN	MYfTRW5ITVJ?
5637	M13Edmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fjbWlEPTB;Mj63NVA{PSEQvF2=	MnfuV2FPT0WU
HOP-92	M4DnOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4XBXGlEPTB;Mj63OFcyPyEQvF2=	M33TbnNCVkeHUh?=
MDA-MB-157	NUjVSlQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVz6OVNTUUN3ME2yMlgzODJ\|IN88US=>	NVLRdXE4W0GQR1XS
NB12	NUnSOINPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX7JR\|UxRTJwOES5NVQh\|ryP	MX7TRW5ITVJ?
DMS-273	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;HdmlEPTB;Mj64OlQ4KM7:TR?=	Mmf3V2FPT0WU
HCC70	MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1HtbmlEPTB;Mj64OlU5QSEQvF2=	NETkUZdUSU6JRWK=
YKG-1	M2m1bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGD4NJBKSzVyPUOuNFM4QDdizszN	MlPMV2FPT0WU
NCI-H28	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnnXFZIUUN3ME2zMlA2OjlzIN88US=>	MXHTRW5ITVJ?
HN	MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX;JR\|UxRTNwME[2N\|Yh\|ryP	M1vndHNCVkeHUh?=
HT-1080	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mn7zTWM2OD1\|LkC4OlA3KM7:TR?=	MkLZV2FPT0WU
HPAF-II	MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnL0TWM2OD1\|LkGwNFY5KM7:TR?=	MnfnV2FPT0WU
U-2-OS	NHLnXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRTNwMUO3PFIh\|ryP	NEfkT5FUSU6JRWK=
SNU-387	Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\BTIg1UUN3ME2zMlE3OzZ2IN88US=>	MoXNV2FPT0WU
Becker	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37kN2lEPTB;Mz6xOlgxQCEQvF2=	MXHTRW5ITVJ?
BHY	M1;CVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3zJR2lEPTB;Mz6yOVU4OSEQvF2=	MVnTRW5ITVJ?
HTC-C3	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoWzTWM2OD1\|LkK5N\|UzKM7:TR?=	MkH6V2FPT0WU
M14	NVnsTm1rT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXQTWM2OD1\|LkOwOlY{KM7:TR?=	MlzMV2FPT0WU
COR-L23	MlHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoPCTWM2OD1\|LkO3Nlc6KM7:TR?=	MULTRW5ITVJ?
C32	NV3zSopST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TIfGlEPTB;Mz60NVUxQCEQvF2=	NIC3ZWxUSU6JRWK=
Mewo	NHzkU4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HPNmlEPTB;Mz60NlE5OiEQvF2=	NFLLcpBUSU6JRWK=
TE-8	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX64d45HUUN3ME2zMlQ5OjV7IN88US=>	MmPYV2FPT0WU
RPMI-2650	NXi5OZZiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvINZpKSzVyPUOuOlA3OzdizszN	NXfjXWVSW0GQR1XS
AGS	M33Sb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnK3TWM2OD1\|Lk[yOFY1KM7:TR?=	MknBV2FPT0WU
MZ2-MEL	NEHXT\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHL4Um9KSzVyPUOuOlYyOzhizszN	NXjzU3RUW0GQR1XS
Calu-3	MmnMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPVXotwUUN3ME2zMlcyOjh5IN88US=>	M4W3eHNCVkeHUh?=
SJSA-1	NHLBOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPnTWM2OD1\|LkexN\|E2KM7:TR?=	M2XWWHNCVkeHUh?=
SW962	M4KyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTNwN{K2N\|Yh\|ryP	M2DvOXNCVkeHUh?=
PC-14	NXnDdmttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnteVc6UUN3ME2zMlc{OjJ{IN88US=>	NGjnSVRUSU6JRWK=
SW1573	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorhTWM2OD1\|Lke1N\|Q5KM7:TR?=	M33FXnNCVkeHUh?=
769-P	NHXHNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlXYTWM2OD1\|LkiyO\|Q{KM7:TR?=	MonjV2FPT0WU
KNS-62	NWLOe\|FpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH:0SnRKSzVyPUOuPVI{OzhizszN	MVvTRW5ITVJ?
NCI-H747	NFfZ[WhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIPmcYlKSzVyPUSuNFU3OzhizszN	MVHTRW5ITVJ?
LN-405	NG\YUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2HaNGlEPTB;ND6xOVczQCEQvF2=	NHjvbY5USU6JRWK=
OVCAR-8	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkP3TWM2OD12LkKyOVQ{KM7:TR?=	Mn6wV2FPT0WU
DMS-114	M1fOWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXvPGVKSzVyPUSuNlM5QTFizszN	NULjeJFuW0GQR1XS
NCI-H2126	MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYjJR\|UxRTRwMkS1OVgh\|ryP	MlH0V2FPT0WU
TCCSUP	NHfsc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHGVJJKSzVyPUSuNlQ4QDhizszN	NVP1ZYdlW0GQR1XS
SK-N-FI	M3;sSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTRwMkWzN\|Ih\|ryP	MXnTRW5ITVJ?
HCE-4	M4H2eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2C3bWlEPTB;ND6yO\|E6PyEQvF2=	NWrySnhEW0GQR1XS
DK-MG	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGXEUm5KSzVyPUSuN\|A{QSEQvF2=	NF;qcnZUSU6JRWK=
RO82-W-1	M4P5U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NITH[VFKSzVyPUSuN\|I2QDRizszN	NUThVmxLW0GQR1XS
A2780	NGX5bldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEThSJBKSzVyPUSuN\|Y3QDJizszN	MYrTRW5ITVJ?
ETK-1	NEjmOXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDlbZJKSzVyPUSuN\|cxPTJizszN	M3TpUHNCVkeHUh?=
FADU	MnPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIXQfFJKSzVyPUSuN\|c1PjdizszN	NF3tT\|JUSU6JRWK=
CAL-12T	NVPQVlkyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\hTWM2OD12LkSxOFE{KM7:TR?=	NWe3dZA6W0GQR1XS
647-V	M2O2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\Ufll5UUN3ME20MlQ1ODJ{IN88US=>	MnH3V2FPT0WU
TGBC1TKB	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PydmlEPTB;ND60OVEyOyEQvF2=	M3vzOXNCVkeHUh?=
LU-99A	M2j6R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoC1TWM2OD12LkS2NFYh\|ryP	NGTBdXFUSU6JRWK=
CAL-33	NGniRopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm[3TWM2OD12LkWyOFU3KM7:TR?=	NXPRcmxQW0GQR1XS
LU-134-A	MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MU\JR\|UxRTRwNUK3OFUh\|ryP	M4DiTnNCVkeHUh?=
NCI-H1355	NHHRNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPkTWM2OD12LkW1NVQ3KM7:TR?=	NITnN4dUSU6JRWK=
RPMI-7951	M2TvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPzb5hKSzVyPUSuOVcxODJizszN	Ml\6V2FPT0WU
TE-1	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYfJR\|UxRTRwNk[xOFMh\|ryP	M1jwTXNCVkeHUh?=
OE33	NU\Md3VrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIn2XlZKSzVyPUSuO\|A2OTFizszN	NH7nW4xUSU6JRWK=
CAL-51	MlzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkLjTWM2OD12LkexNFgzKM7:TR?=	NWX5bplpW0GQR1XS
SW1783	NUXLTlU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1vXWGlEPTB;ND63OVMxQCEQvF2=	M4fWV3NCVkeHUh?=
BT-474	Mn;vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoezTWM2OD12Lke2N\|g1KM7:TR?=	Mmq1V2FPT0WU
KYSE-520	NF\3OJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYfJR\|UxRTRwOEezPVIh\|ryP	MYfTRW5ITVJ?
8-MG-BA	NE[4V\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmryTWM2OD12Lki4OVU4KM7:TR?=	MVHTRW5ITVJ?
IA-LM	Mor3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1zaNmlEPTB;ND65PVQ{PSEQvF2=	MUPTRW5ITVJ?
SW954	NWHsVZFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTRwOUm0OFMh\|ryP	MVPTRW5ITVJ?
RPMI-8226	M2PxSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTVwMEW0OlEh\|ryP	NUPkbZR2W0GQR1XS
MKN1	MmHtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjDTWM2OD13LkC3PVI4KM7:TR?=	NVPZZY5QW0GQR1XS
A375	M1voNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTVwMEmyOVYh\|ryP	M4fpPHNCVkeHUh?=
8305C	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTVwMEm4PFch\|ryP	MYXTRW5ITVJ?
CAL-62	MnO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXHJR\|UxRTVwMUiyOVkh\|ryP	MWLTRW5ITVJ?
NB10	MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTVwMkK3OFQh\|ryP	MmP3V2FPT0WU
OC-314	NFzNfYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV;MT2hxUUN3ME21MlM4PDR2IN88US=>	MVzTRW5ITVJ?
PSN1	M3jV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVznSWk1UUN3ME21MlM5Ojh4IN88US=>	MU\TRW5ITVJ?
GR-ST	NImx[YNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTVwM{izNlIh\|ryP	NFix[4hUSU6JRWK=
P12-ICHIKAWA	Mo\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rTdmlEPTB;NT60NFEh\|ryP	NFrzfINUSU6JRWK=
NCI-H1092	MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTVwNEGxOFgh\|ryP	NU\QTnNZW0GQR1XS
SCC-4	M37Eb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTVwNEGzOVUh\|ryP	NV3pNG9{W0GQR1XS
TE-6	M2XTTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXqTWM2OD13LkSxPFE3KM7:TR?=	M1jF[nNCVkeHUh?=
DOHH-2	MmewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnGXZJKSzVyPUWuOFIzPDhizszN	NVHBcVA2W0GQR1XS
SW684	MmrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF7yTWJKSzVyPUWuOlY{QDVizszN	MYfTRW5ITVJ?
CP50-MEL-B	M1n2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXTobGR2UUN3ME21MlY5Pjh2IN88US=>	M1;pNnNCVkeHUh?=
UM-UC-3	MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{jm[2lEPTB;NT63NlI{OSEQvF2=	MnOyV2FPT0WU
LC-2-ad	NV;NTJZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlOzTWM2OD13Lke4NlUyKM7:TR?=	M4nleXNCVkeHUh?=
PC-3	MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXz2ZZZoUUN3ME21MlkyPjF3IN88US=>	MWHTRW5ITVJ?
CAN	MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlWyTWM2OD13LkmyPFIh\|ryP	NVGwNlRjW0GQR1XS
ESS-1	NH21NHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3K4TWlEPTB;NT65O\|g3QSEQvF2=	M3Tw[nNCVkeHUh?=
ATN-1	NFvMRodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPVTWM2OD14LkC1OVY5KM7:TR?=	MVTTRW5ITVJ?
BxPC-3	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;oVHBKSzVyPU[uNFgzOTlizszN	MXnTRW5ITVJ?
KYSE-150	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX7ueGhZUUN3ME22MlEzPDd4IN88US=>	MVnTRW5ITVJ?
RPMI-8866	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlG2TWM2OD14LkG5NVY{KM7:TR?=	M{fqeXNCVkeHUh?=
SW780	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH31Z\|ZKSzVyPU[uNlA1OiEQvF2=	M2Gw[3NCVkeHUh?=
A388	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGLHcGVKSzVyPU[uNlMyOTVizszN	M3;FenNCVkeHUh?=
NCI-H1437	M2C3Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2frZWlEPTB;Nj6yOFA4OyEQvF2=	M3jvUHNCVkeHUh?=
NCI-H1755	MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTZwM{[2NVIh\|ryP	MlOwV2FPT0WU
LS-123	NWXVUVJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3GdIJKSzVyPU[uOFA2OjFizszN	MWjTRW5ITVJ?
CaR-1	NVzoPWZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XReGlEPTB;Nj60OlM4OyEQvF2=	MknHV2FPT0WU
RT-112	MkDTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH7ZWGpKSzVyPU[uOlA{OzhizszN	NFOzVlRUSU6JRWK=
CGT	NXzNNFFwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvrSnpKSzVyPU[uO\|M3QDFizszN	NVTPVZlRW0GQR1XS
SW626	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUi3VIQ1UUN3ME22Mlc{QTR4IN88US=>	M3rtOnNCVkeHUh?=
AsPC-1	M33K[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTZwN{S1NFch\|ryP	MWDTRW5ITVJ?
SBC-5	M{DXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYq2eopZUUN3ME22Mlk4Ojl5IN88US=>	Mln4V2FPT0WU
SF539	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEnudJZKSzVyPU[uPVk{OzNizszN	MY\TRW5ITVJ?
TI-73	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17SfWlEPTB;Nz6wOlI5PSEQvF2=	M3TFPXNCVkeHUh?=
MHH-ES-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUDJR\|UxRTdwMEe3OlIh\|ryP	MUDTRW5ITVJ?
KYSE-510	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4faXWlEPTB;Nz6wPFQ{OiEQvF2=	M{TQVHNCVkeHUh?=
EW-1	NG\KZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXsTWM2OD15LkO2PVk3KM7:TR?=	MmftV2FPT0WU
SK-OV-3	M1Xofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkXzTWM2OD15LkO5OFMzKM7:TR?=	NYnrRXY6W0GQR1XS
MC-IXC	NWTyNY1tT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvRR5J5UUN3ME23MlQyQTd{IN88US=>	NHHvemlUSU6JRWK=
HSC-2	NVTvSHNbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XSUmlEPTB;Nz60NlcxPSEQvF2=	NYnyRXFlW0GQR1XS
NCI-H2342	M2jxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\TTWM2OD15LkWxOFkh\|ryP	MXnTRW5ITVJ?
NCI-H1792	MnPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mlf6TWM2OD15LkWxO\|EyKM7:TR?=	NVv4U5Q1W0GQR1XS
HT-1376	NHjOcndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moi2TWM2OD15Lki3O\|c5KM7:TR?=	MXTTRW5ITVJ?
EW-13	M3HIfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULLWWVIUUN3ME23Mlg6QTd5IN88US=>	NHrEfJJUSU6JRWK=
no-11	NV3rN5JFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfyTWM2OD15LkmwNVc1KM7:TR?=	NIrpN5VUSU6JRWK=
Daoy	NHPrZ\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHqTWM2OD15Lkm0N\|IyKM7:TR?=	MoXrV2FPT0WU
COLO-800	MoLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjudIV1UUN3ME24MlA1OTZ{IN88US=>	M13sRnNCVkeHUh?=
GB-1	MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRThwME[1OlUh\|ryP	MVfTRW5ITVJ?
SJRH30	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWfYW4hWUUN3ME24MlE2QDd6IN88US=>	MW\TRW5ITVJ?
NCI-H2291	M3XycGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPITppQUUN3ME24MlI6OTh5IN88US=>	NH[xXWdUSU6JRWK=
J82	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmXLTWM2OD16LkK5OFkyKM7:TR?=	NIqzdGFUSU6JRWK=
NCI-H596	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEXPc4RKSzVyPUiuN\|E1PTNizszN	NFu2UJZUSU6JRWK=
RERF-LC-MS	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7ETWM2OD16LkO0PFU3KM7:TR?=	NG\mNGVUSU6JRWK=
RH-18	NYjBbZk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHLZU3NKSzVyPUiuN\|UxPDZizszN	NXXxVoZvW0GQR1XS
SW48	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRThwNUm0OVMh\|ryP	NH7td4RUSU6JRWK=
RD	NV\xcIRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRThwNUmzPVEh\|ryP	M{i3SnNCVkeHUh?=
MS-1	NHnCfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIH1N3pKSzVyPUiuOlE{QDdizszN	NX\VeYJVW0GQR1XS
ES6	M1yzTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRThwN{OxNVkh\|ryP	NI[4WXlUSU6JRWK=
TE-12	NGDCTZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLKO4tRUUN3ME24Mlc4PTB3IN88US=>	NF;J[2hUSU6JRWK=
DBTRG-05MG	M3j6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\aNWlEPTB;OD65NVIyPyEQvF2=	Mne3V2FPT0WU
KINGS-1	M4jCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUW5UFJHUUN3ME24MlkzQTN6IN88US=>	MYrTRW5ITVJ?
HLE	M1rlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUDzW3FRUUN3ME24Mlk{Pzh3IN88US=>	NFP0TWxUSU6JRWK=
MHH-NB-11	MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTlwMEG4N\|kh\|ryP	NIL2O3hUSU6JRWK=
U-87-MG	NVKwVGNoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTlwMkSzNlEh\|ryP	MmD6V2FPT0WU
MN-60	NH:4SFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPBXI5KSzVyPUmuNlQ2PDJizszN	NVi1TopGW0GQR1XS
SAS	M4XXV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTlwMkW1PFEh\|ryP	NYntWYxPW0GQR1XS
NCI-H446	NXz2ZXRVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1jXXWlEPTB;OT6zOlEh\|ryP	MojpV2FPT0WU
C-33-A	NX:1VmhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LkZmlEPTB;OT60N\|k5QCEQvF2=	NEDveJlUSU6JRWK=
RXF393	NIr1dHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDqbZFKSzVyPUmuOFcxODJizszN	NYHRZZp{W0GQR1XS
CGTH-W-1	NIq2S5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPITWM2OD17LkS5N\|g1KM7:TR?=	NFfj[HhUSU6JRWK=
RCM-1	M3XlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvlTWM2OD17Lk[zPFAyKM7:TR?=	MUPTRW5ITVJ?
SN12C	NFXmO5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvPOVRKSzVyPUmuOlU{OzhizszN	M2fJdHNCVkeHUh?=
KLE	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYf0UFQ5UUN3ME25MlcxODB7IN88US=>	M1n4cXNCVkeHUh?=
EFO-21	M{HDW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFnFPHRKSzVyPUmuO\|c{QDJizszN	Mo\0V2FPT0WU
KYSE-70	M1P5Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTlwOEiwNVEh\|ryP	MYjTRW5ITVJ?
D-247MG	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\iTYdNUUN3ME2xNE4xPTZ6IN88US=>	MV;TRW5ITVJ?
MPP-89	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV\JR\|UxRTFyLkC5OFYh\|ryP	NIm4TWZUSU6JRWK=
RVH-421	MoTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVT1[IpJUUN3ME2xNE4yPTB3IN88US=>	MWjTRW5ITVJ?
NCI-H460	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{f1fmlEPTB;MUCuNlgxPiEQvF2=	M1vl[3NCVkeHUh?=
NOMO-1	Ml7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33o[WlEPTB;MUCuN\|U{OiEQvF2=	MX\TRW5ITVJ?
DEL	M{TGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjNdpNKSzVyPUGwMlM4QTRizszN	M2r3VXNCVkeHUh?=
HT55	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTFyLk[yNFUh\|ryP	M1jEWXNCVkeHUh?=
MC116	M3n0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvuOHc2UUN3ME2xNE43PjV3IN88US=>	MkfuV2FPT0WU
BB30-HNC	NG\6[FhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVLSelJTUUN3ME2xNE43PjlizszN	MlPGV2FPT0WU
DJM-1	NWrJPFd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3;rVGlEPTB;MUCuOlk1QSEQvF2=	M1;DVnNCVkeHUh?=
ZR-75-30	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTFyLkm0OFEh\|ryP	NU[4TXFsW0GQR1XS
U-118-MG	NV:4eFIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2n5XmlEPTB;MUCuPVg6PiEQvF2=	MlKwV2FPT0WU
MSTO-211H	NH;qbpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXjTZNDUUN3ME2xNU4xPzF4IN88US=>	NF2xO3dUSU6JRWK=
SW837	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoTYTWM2OD1zMT6wPVQ6KM7:TR?=	MV\TRW5ITVJ?
HuCCT1	NY\ZZ4ZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTFzLkGyPFEh\|ryP	MoXOV2FPT0WU
RCC10RGB	NXq5OlJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPldG9KSzVyPUGxMlE{PSEQvF2=	NXP1d2N[W0GQR1XS
NMC-G1	NX[2NldnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MU\JR\|UxRTFzLkG0PVMh\|ryP	NV3HeXJOW0GQR1XS
NCI-H650	NYjjTZdTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYi3R2YxUUN3ME2xNU4{Pzl2IN88US=>	MWHTRW5ITVJ?
HEC-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NELhOo5KSzVyPUGxMlQ{OjhizszN	NXrJTHBqW0GQR1XS
DU-4475	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGrlO3VKSzVyPUGxMlc{QTNizszN	NX6xO5duW0GQR1XS
DSH1	MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH:0UYxKSzVyPUGxMlc3ODZizszN	NX\COIlHW0GQR1XS
HCC1569	NYPXZ2xmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRTFzLke2O\|gh\|ryP	M3:0S3NCVkeHUh?=
HCC1187	M1O0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkiyTWM2OD1zMT64OVg5KM7:TR?=	NYC1SG1jW0GQR1XS
EW-11	MlSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWS2VoNzUUN3ME2xNU46PDd2IN88US=>	MUXTRW5ITVJ?
LB2518-MEL	NFq5b2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTF{LkC1PUDPxE1?	M{H1cnNCVkeHUh?=
KALS-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUC5ZYlsUUN3ME2xNk45PTV\|IN88US=>	NGXxOWtUSU6JRWK=
8505C	NVjsdFg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF:3XGlKSzVyPUGyMlg5PSEQvF2=	NFW4TJFUSU6JRWK=
SK-N-DZ	NHTlRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF7nfVhKSzVyPUGzMlA1PTNizszN	MmfHV2FPT0WU
CHP-134	NEjtVZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTF\|LkGxOVgh\|ryP	NGjIcIpUSU6JRWK=
HCE-T	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzXTWM2OD1zMz6yN\|Y1KM7:TR?=	NUfiTIliW0GQR1XS
LB-831-BLC	NULXR4pWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1LrdmlEPTB;MUOuOlI1PiEQvF2=	NWXSSopWW0GQR1XS
OVCAR-4	M1PIcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnK2TWM2OD1zMz62OVI1KM7:TR?=	MmXaV2FPT0WU
SW756	MkPKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2DYfGlEPTB;MUOuO\|I1PiEQvF2=	NHizbZpUSU6JRWK=
OCUB-M	NH7CcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2fmNmlEPTB;MUOuPFE2PiEQvF2=	NVTyR5RRW0GQR1XS
SW982	M4\5RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWfJR\|UxRTF\|LkiyO\|Yh\|ryP	MULTRW5ITVJ?
DB	MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmjiTWM2OD1zMz64N\|g1KM7:TR?=	NX;RXW5mW0GQR1XS
H-EMC-SS	NIXCN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV\JR\|UxRTF\|LkmxN\|kh\|ryP	MlPXV2FPT0WU
VMRC-RCZ	NGPw[oNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIDUcIRKSzVyPUG0MlAxOTVizszN	NV:4UldEW0GQR1XS
CAKI-1	MlTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHe2U4VKSzVyPUG0MlAyOzJizszN	NVm2dolKW0GQR1XS
GI-1	MmfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NET0SVNKSzVyPUG0MlA3PThizszN	MWLTRW5ITVJ?
Ca9-22	MmfzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nPVmlEPTB;MUSuOlA2PCEQvF2=	M{PZXnNCVkeHUh?=
TE-5	NWjhN3lqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfPbG5qUUN3ME2xOE44OjB6IN88US=>	MXrTRW5ITVJ?
EFO-27	NGfZWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF30cFNKSzVyPUG0Mlc3OjJizszN	NWTuSHA3W0GQR1XS
CAL-72	NF;lOWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTF2Lke3PFMh\|ryP	M4DpN3NCVkeHUh?=
GP5d	NIfYeZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvnempKSzVyPUG1MlA1PzRizszN	M1XMZnNCVkeHUh?=
CAS-1	Mof2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3KTWM2OD1zNT6wOlYh\|ryP	NGTEZXRUSU6JRWK=
A2058	M{LTO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXsWIN{UUN3ME2xOU42PjN6IN88US=>	Moi3V2FPT0WU
PANC-08-13	Mn7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LHfGlEPTB;MUWuOlg2QSEQvF2=	NXzuZ5J5W0GQR1XS
Detroit562	NWXwdmtwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\qNYtKSzVyPUG1MlkyOzlizszN	NIPZfIhUSU6JRWK=
PANC-10-05	M2\j[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF;Nc5ZKSzVyPUG2MlA5OjFizszN	NWrFUFY1W0GQR1XS
KOSC-2	MkfUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\tTWM2OD1zNj6xNVI2KM7:TR?=	MVzTRW5ITVJ?
GT3TKB	NInVNmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGi4OXpKSzVyPUG2MlE6QDFizszN	MnLpV2FPT0WU
KM-H2	MlHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4DiRmlEPTB;MU[uN\|Y1PiEQvF2=	NGfRV41USU6JRWK=
LB771-HNC	NXnQXlFzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnLqTWM2OD1zNj60OFIzKM7:TR?=	NV3qN5UyW0GQR1XS
SF268	M3n4fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTF4LkS1NkDPxE1?	M1u3[nNCVkeHUh?=
OE19	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmjLTWM2OD1zNj61NlQh\|ryP	MmO4V2FPT0WU
MLMA	M4Pr[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PxN2lEPTB;MU[uOVU4OSEQvF2=	MoTsV2FPT0WU
MDA-MB-231	NUm1OFhIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHsTWM2OD1zNj63NVM3KM7:TR?=	M{jFWHNCVkeHUh?=
TGW	NYnrNo5iT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTF4LkixNFIh\|ryP	MnLiV2FPT0WU
MDA-MB-453	NH;4UXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHWVXRKSzVyPUG3MlAxODNizszN	MkDFV2FPT0WU
SNU-C2B	NFrXdoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWXUeWVlUUN3ME2xO{4xOjN5IN88US=>	NH7WT4tUSU6JRWK=
A427	MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\YdpVKSzVyPUG3MlI{OzRizszN	M1fSOXNCVkeHUh?=
SK-MEL-2	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXP2dYU4UUN3ME2xO{4{OjF\|IN88US=>	M163S3NCVkeHUh?=
KURAMOCHI	NFXQSGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX\JR\|UxRTF5LkO4PVch\|ryP	NYDweY1ZW0GQR1XS
IST-MEL1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3y2UGlEPTB;MUeuPVE5OiEQvF2=	MXTTRW5ITVJ?
NCI-H1793	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7NTJZKSzVyPUG4MlE2QDFizszN	NIDrNVhUSU6JRWK=
HCC1395	NXfVU2t2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHiTWM2OD1zOD61OlEyKM7:TR?=	M1nwUHNCVkeHUh?=
NUGC-3	NGn6XmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE\CNI9KSzVyPUG4MlY2QDRizszN	MnLIV2FPT0WU
BB65-RCC	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTF6Lk[2PUDPxE1?	NXHGUXFVW0GQR1XS
RMG-I	M3;0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mo\VTWM2OD1zOD63N\|gzKM7:TR?=	MYHTRW5ITVJ?
LS-513	NYXRV2VHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGnHXWZKSzVyPUG4MlkzOjhizszN	MV7TRW5ITVJ?
MFM-223	NGj0Z4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmfPTWM2OD1zOT6wO\|E3KM7:TR?=	MX\TRW5ITVJ?
NCI-H727	M1OzW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPOdmZKSzVyPUG5MlMzQTVizszN	MojxV2FPT0WU
KP-4	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlGwTWM2OD1zOT64OVMyKM7:TR?=	NF\QNFFUSU6JRWK=
NB13	MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXmTWM2OD1zOT64PFM6KM7:TR?=	MniyV2FPT0WU
UACC-893	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlewTWM2OD1zOT65O\|U4KM7:TR?=	M3zsOXNCVkeHUh?=
HT-1197	NH7ZOHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITMdIFKSzVyPUKwMlI6PThizszN	M{DOW3NCVkeHUh?=
NCI-H2029	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnHZTWM2OD1{MD6zNlY3KM7:TR?=	MmCyV2FPT0WU
GI-ME-N	M4S4XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{naVWlEPTB;MkCuN\|M4OyEQvF2=	MUjTRW5ITVJ?
OVCAR-3	MmTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{TUPGlEPTB;MkCuOVgzOiEQvF2=	MXjTRW5ITVJ?
HD-MY-Z	NEfFWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXjJR\|UxRTJzLkO2PVYh\|ryP	M4qxRXNCVkeHUh?=
NTERA-S-cl-D1	M{XPe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGjNU25KSzVyPUKxMlY4OjJizszN	M{X1d3NCVkeHUh?=
SCH	M3[xfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXS5NlRWUUN3ME2yNk41QTZizszN	MnPDV2FPT0WU
KARPAS-299	M1HOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIq2WG5KSzVyPUKzMlM5QDdizszN	NGPKN5VUSU6JRWK=
NCI-H1650	M2DvUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\z[plkUUN3ME2yN{46OjRzIN88US=>	M1q1OnNCVkeHUh?=
ACHN	MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoP1TWM2OD1{ND60OlU3KM7:TR?=	NEmzPXpUSU6JRWK=
M059J	NWX0b\|RTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTVdXdyUUN3ME2yOE42PjN2IN88US=>	NYKzOWduW0GQR1XS
AM-38	NWLjW2U{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmD0TWM2OD1{NT60PFEh\|ryP	MXnTRW5ITVJ?
KG-1	MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTJ3LkW0PVQh\|ryP	MWHTRW5ITVJ?
COLO-824	MnvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2O2NmlEPTB;MkWuOVU6QSEQvF2=	MYHTRW5ITVJ?
NCI-H1155	NY\I[Wo1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{PYUGlEPTB;MkWuOVg1PyEQvF2=	MnHKV2FPT0WU
NCI-H441	MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nSbGlEPTB;MkWuO\|Q3PSEQvF2=	M{\kNnNCVkeHUh?=
J-RT3-T3-5	NYXjZlNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXfJR\|UxRTJ4LkOwNlch\|ryP	MlTpV2FPT0WU
JEG-3	NIjxRnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjxTWM2OD1{Nj62PFA2KM7:TR?=	M1XlO3NCVkeHUh?=
RKO	M16ydGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjTfG1JUUN3ME2yOk44PjN{IN88US=>	M4mwcHNCVkeHUh?=
CAL-85-1	NGroTFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEe1d\|NKSzVyPUK3MlIyOThizszN	MmDHV2FPT0WU
CAL-120	M13MVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rYWWlEPTB;MkeuOlkyPCEQvF2=	NET3[nlUSU6JRWK=
NCI-H2452	NYD3b3UyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILQZ5VKSzVyPUK3Mlc4OTZizszN	NI\mSXZUSU6JRWK=
NCI-H1395	NGHYTI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1GyRWlEPTB;MkeuO\|g{OyEQvF2=	MUnTRW5ITVJ?
KYSE-450	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUfwPFRrUUN3ME2yO{46QDZ{IN88US=>	M{nu[HNCVkeHUh?=
S-117	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTJ7LkO4OVch\|ryP	NVTaNZFvW0GQR1XS
SW13	M3Tmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH32SY5KSzVyPUK5Mlg2OTlizszN	MXXTRW5ITVJ?
ES3	MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jTVWlEPTB;M{CuN\|c{OyEQvF2=	MoS3V2FPT0WU
HCT-116	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnLPTWM2OD1\|MD61OVU1KM7:TR?=	NFmzSppUSU6JRWK=
NCI-H1693	NVnNbpBVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfwTWM2OD1\|MD61PVQzKM7:TR?=	M2TZb3NCVkeHUh?=
VM-CUB-1	NUPkSVJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIPXU4dKSzVyPUOwMlY1OTNizszN	M4LNNXNCVkeHUh?=
NCI-H2170	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DDSWlEPTB;M{GuOVc5PCEQvF2=	Mn7hV2FPT0WU
ALL-PO	NUXWNpY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnmwTWM2OD1\|MT64OFI5KM7:TR?=	MV;TRW5ITVJ?
NCI-H661	M1vnSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3u1e2lEPTB;M{KuNFYzOyEQvF2=	Mnn2V2FPT0WU
NCI-H2347	M4jVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrnTWM2OD1\|Mj60PFM4KM7:TR?=	NEDHNItUSU6JRWK=
FTC-133	NGX6UlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjJR\|UxRTN{LkewOkDPxE1?	MoDnV2FPT0WU
COLO-829	MlHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\tTWM2OD1\|Mz6zOFY4KM7:TR?=	NHy5SJZUSU6JRWK=
GOTO	Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTN\|LkWyOVgh\|ryP	M4PMe3NCVkeHUh?=
YAPC	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHnsTZJKSzVyPUOzMlgyPTlizszN	MYXTRW5ITVJ?
LCLC-103H	MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmC1TWM2OD1\|ND6xOlI1KM7:TR?=	MWrTRW5ITVJ?
SiHa	MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2rSNGlEPTB;M{SuN\|gyPyEQvF2=	M2CzenNCVkeHUh?=
LK-2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DrV2lEPTB;M{SuOVcxQCEQvF2=	MnO5V2FPT0WU
KP-N-YS	MkXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWf0UZJqUUN3ME2zOE44OjB{IN88US=>	NUTFVnNmW0GQR1XS
NCI-SNU-1	M3nWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;yZ\|NKSzVyPUO1MlE4QSEQvF2=	MkPNV2FPT0WU
KNS-81-FD	MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33DTWlEPTB;M{WuOlY{KM7:TR?=	MlfnV2FPT0WU
SCC-9	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2rVZ2lEPTB;M{[uO\|E1PiEQvF2=	MYXTRW5ITVJ?
SH-4	MnG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIHxdplKSzVyPUO2Mlc{KM7:TR?=	NVzSOlltW0GQR1XS
HCC-1954	MmO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXr5[483UUN3ME2zO{4zPzJ7IN88US=>	NWPHTYhOW0GQR1XS
BALL-1	Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX3wVlJUUUN3ME2zO{42OzF4IN88US=>	M1j5WnNCVkeHUh?=
BE-13	NGnkRlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4roZWlEPTB;M{euO\|AyQCEQvF2=	NEfKTVFUSU6JRWK=
COLO-678	NYXEflNET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELNU21KSzVyPUO3Mlk1OzdizszN	NVvFc4VQW0GQR1XS
SK-MEL-3	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3v6RWlEPTB;M{iuNlM6PyEQvF2=	MlX5V2FPT0WU
OAW-28	NFvkS3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1K2fWlEPTB;M{iuOlM6KM7:TR?=	M3XxW3NCVkeHUh?=
CAMA-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTN6Lkm2PVEh\|ryP	NYqzZoVsW0GQR1XS
C2BBe1	NHHCbYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX\vXWNHUUN3ME2zPU45OThizszN	NVKyOVdYW0GQR1XS
A3-KAW	NYPSZ\|VjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTRyLkO2OlEh\|ryP	MU\TRW5ITVJ?
SK-MEL-24	NH;BU3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\rTWM2OD12MD61PVMyKM7:TR?=	NXnLTWVSW0GQR1XS
KYSE-140	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jlTGlEPTB;NECuO\|E3PSEQvF2=	MmDwV2FPT0WU
MOLT-16	NFrYfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnP6TWM2OD12MT6xOVM3KM7:TR?=	MkfqV2FPT0WU
CFPAC-1	M4nhfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTR{LkWyNVEh\|ryP	NIPXfIhUSU6JRWK=
NB14	M1zqN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVzqc3Z2UUN3ME20Nk44ODJ5IN88US=>	NVjBOm5CW0GQR1XS
COLO-792	NHHKNFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjFTWM2OD12Mj64PVYyKM7:TR?=	MnvaV2FPT0WU
RH-1	MonTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTR\|LkS4N\|Yh\|ryP	NGXkS45USU6JRWK=
NCI-H522	M37IbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\L[mlEPTB;NESuN\|U3QCEQvF2=	NIPkR4hUSU6JRWK=
Ca-Ski	MnfhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFrZc5ZKSzVyPUS0MlgyOTRizszN	NIfvd2JUSU6JRWK=
KGN	NUTHRVJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLL[Zk{UUN3ME20PE4{ODZ\|IN88US=>	MYjTRW5ITVJ?
UACC-62	MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFHMTYpKSzVyPUS4MlQxPzJizszN	MWPTRW5ITVJ?
NCI-H358	Mm[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnfYTWM2OD12OT6zNFE5KM7:TR?=	MXrTRW5ITVJ?
LS-411N	NELLbYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\MWotKSzVyPUS5MlMyOThizszN	M4DhZnNCVkeHUh?=
IST-MES1	MlXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXzJR\|UxRTR7LkW2NlUh\|ryP	M1zOVnNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-FoxO3a / FoxO3a / PUMA; PubMed: 29137323 Oncotarget HCT116 cells were treated with 4μmol/L NVP-BKM120 or 4μmol/L Pictilisib for 24 hours. Indicated protein levels were analyzed by Western blotting. p-S6RP / S6RP; PubMed: 30042442 Cell Death Dis Western blot analysis of proteins as indicated in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. Vinculin was used as a loading control. p-4EBP1 / 4EBP1; PubMed: 25857298 Oncotarget Cells were treated with 0.5 μM GDC-0941 for the indicated time course and then collected for Western blot analysis of p-4EBP1. p-LRP6 / LRP6; PubMed: 25857298 Oncotarget MDAMB-231, HCC1937 and MCF7 cells were treated with 0.5 µM GDC-0941 for 1 hr, and cell lysates were used for immunoblot analyses. p-PAK / PAK1 / p-CRAF / RAF / p-MEK / MEK / p-ERK / ERK; PubMed: 24327733 Proc Natl Acad Sci U S A Cells were treated with 1 μM GDC-0941 for the indicated times, and lysates were probed with the indicated antibodies. Independent experiments were performed at least three times, and a representative result is shown.	29137323 30042442 25857298 24327733
Immunofluorescence	p65; PubMed: 30042442 Cell Death Dis Representative images of immunofluorescent staining of p65 cellular localization in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. 4T1 cells were cultured alone or co-cultured with RAW264.7 macrophages. Representative images of three independent experiments are shown. beta-catenin; PubMed: 25857298 Oncotarget Cells were seeded on coverslips the day before the experiment and treated with 0.5 µM GDC-0941 for 18 hr. The immunofluorescence (IF) of beta-catenin is indicated as red fluorescence, and double staining with DAPI is blue. Magnification: 400 X for the left three panels. The right panel shows enlarged images from the white squares.	30042442 25857298
Growth inhibition assay	Cell viability; PubMed: 27117832 J Thorac Oncol The viability of the indicated cells treated with increasing concentrations of GDC-0941 (ranging from 70nM to 20 μM) for 72 hours, determined by CellTiter Glo Viability assay. The IC50 concentrations were calculated using GraphPad Prism program. The assay was performed in triplicate, and the error bars represent standard deviations.	27117832

In vivo

GDC-0941 shows limited microsomal metabolism, resulting in 78% oral bioavailability ^[5]. Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. ^[1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. ^[2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. ^[4]

Protocol

Kinase Assay: ^[1]	+ Expand Scintillation proximity assay: Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl₂, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-³³P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.
Cell Research: ^[2]	+ Expand Cell lines: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 48 and 72 hours Method: Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISA^plus assay are used to detect caspase 3/7 activity, and apoptosis, respectively. (Only for Reference)
Animal Research: ^[2]	+ Expand Animal Models: NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdc^scid mice implanted subcutaneously with BT474-M1 cells Formulation: Dissolved in 10% DMSO, 5% Tween 20, 85% water Dosages: ~150 mg/kg/day Administration: Oral gavage (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	44 mg/mL (85.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Pictilisib (GDC-0941) SDF

Molecular Weight	513.64
Formula	C₂₃H₂₇N₇O₃S₂
CAS No.	957054-30-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	RG7321

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02092831	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	April 2014	Phase 1
NCT01740336	Completed	Drug: GDC-0941\|Drug: Placebo\|Drug: Paclitaxel	Breast Cancer	Genentech Inc.	February 6 2013	Phase 2
NCT01474668	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	October 2011	Phase 1
NCT01240226	Completed	Drug: GDC-0941\|Drug: ketoconazole	Healthy Volunteer	Genentech Inc.	November 2010	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Pan PI3K Inhibitor

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Dactolisib (BEZ235, NVP-BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.
Buparlisib (BKM120, NVP-BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)

Cited by 114 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Pictilisib (GDC-0941) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)

Cited by 114 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Pictilisib (GDC-0941) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

Tech Support

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)